MediPharm Labs Future Growth

Future criteria checks 1/6

MediPharm Labs is forecast to grow earnings and revenue by 77.8% and 18.1% per annum respectively while EPS is expected to grow by 70.5% per annum.

Key information

77.8%

Earnings growth rate

70.5%

EPS growth rate

Pharmaceuticals earnings growth63.8%
Revenue growth rate18.1%
Future return on equityn/a
Analyst coverage

Low

Last updated15 Nov 2024

Recent future growth updates

Recent updates

MediPharm Labs Corp. (TSE:LABS) Doing What It Can To Lift Shares

Oct 11
MediPharm Labs Corp. (TSE:LABS) Doing What It Can To Lift Shares

MediPharm Labs (TSE:LABS) Is Using Debt Safely

May 29
MediPharm Labs (TSE:LABS) Is Using Debt Safely

Market Might Still Lack Some Conviction On MediPharm Labs Corp. (TSE:LABS) Even After 31% Share Price Boost

Mar 23
Market Might Still Lack Some Conviction On MediPharm Labs Corp. (TSE:LABS) Even After 31% Share Price Boost

Does MediPharm Labs (TSE:LABS) Have A Healthy Balance Sheet?

Jan 10
Does MediPharm Labs (TSE:LABS) Have A Healthy Balance Sheet?

MediPharm Labs (TSE:LABS) Has Debt But No Earnings; Should You Worry?

Sep 06
MediPharm Labs (TSE:LABS) Has Debt But No Earnings; Should You Worry?

MediPharm Labs Corp. (TSE:LABS) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable

Apr 17
MediPharm Labs Corp. (TSE:LABS) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable

Time To Worry? Analysts Just Downgraded Their MediPharm Labs Corp. (TSE:LABS) Outlook

Aug 20
Time To Worry? Analysts Just Downgraded Their MediPharm Labs Corp. (TSE:LABS) Outlook

Some Analysts Just Cut Their MediPharm Labs Corp. (TSE:LABS) Estimates

May 21
Some Analysts Just Cut Their MediPharm Labs Corp. (TSE:LABS) Estimates

Things Look Grim For MediPharm Labs Corp. (TSE:LABS) After Today's Downgrade

Apr 06
Things Look Grim For MediPharm Labs Corp. (TSE:LABS) After Today's Downgrade

Is MediPharm Labs (TSE:LABS) Using Too Much Debt?

Mar 07
Is MediPharm Labs (TSE:LABS) Using Too Much Debt?

Does MediPharm Labs (TSE:LABS) Have A Healthy Balance Sheet?

Aug 18
Does MediPharm Labs (TSE:LABS) Have A Healthy Balance Sheet?

Some MediPharm Labs Corp. (TSE:LABS) Analysts Just Made A Major Cut To Next Year's Estimates

May 23
Some MediPharm Labs Corp. (TSE:LABS) Analysts Just Made A Major Cut To Next Year's Estimates

Earnings and Revenue Growth Forecasts

TSX:LABS - Analysts future estimates and past financials data (CAD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202549-4N/AN/A1
12/31/202441-10N/AN/A1
9/30/202439-12-3-2N/A
6/30/202438-13-5-5N/A
3/31/202437-14-11-11N/A
12/31/202333-13-13-12N/A
9/30/202330-16-15-14N/A
6/30/202328-20-14-14N/A
3/31/202323-26-14-14N/A
12/31/202222-30-17-16N/A
9/30/202222-46-21-20N/A
6/30/202220-46-18-17N/A
3/31/202221-48-13-13N/A
12/31/202122-55-14-13N/A
9/30/202122-64-17-16N/A
6/30/202122-72-27-26N/A
3/31/202130-63-33-28N/A
12/31/202036-66-45-38N/A
9/30/202062-39-46-29N/A
6/30/2020101-20-67-40N/A
3/31/2020118-15-74-45N/A
12/31/20191292-58-25N/A
9/30/20191071-54-27N/A
6/30/201964-4-36-12N/A
3/31/201932-8-23-4N/A
12/31/201810-8-26-11N/A
9/30/2018N/A-6-23-10N/A
6/30/2018N/A-4N/A-4N/A
3/31/2018N/A-2N/A-3N/A
12/31/2017N/A-1N/A0N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: LABS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: LABS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: LABS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: LABS's revenue (18.1% per year) is forecast to grow faster than the Canadian market (7.4% per year).

High Growth Revenue: LABS's revenue (18.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if LABS's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/08 05:06
End of Day Share Price 2025/01/08 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

MediPharm Labs Corp. is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Aaron GreyAlliance Global Partners
Tamy ChenBMO Capital Markets Equity Research
Kimberly Thompson-HedlinCanaccord Genuity